Biomay AG
Biomay AG is a privately held Vienna-based CDMO offering GMP contract manufacturing of plasmid DNA, mRNA, and recombinant proteins, plus off-the-shelf catalog products, to biotech and pharma clients in Europe and the United States.
- Company typePrivate
- Founded1984
- HeadquartersVienna, Austria
- Headcount—
- GTM typeB2B
- OfferingServices
What Biomay AG does
Biomay AG is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Vienna, Austria, operating as a one-stop manufacturer of three core biomolecules: plasmid DNA (pDNA), messenger RNA (mRNA), and recombinant proteins. Founded in 1984 and operating GMP manufacturing services since 2009, the company transitioned to a pure-play CDMO in 2019 and runs two integrated GMP facilities in Vienna totaling approximately 6,000 sqm — a 4,000 sqm headquarters in Aspern Seestadt focused on pDNA and recombinant proteins, and a 2,000 sqm mRNA Competence Center in the city's 9th district covering IVT, LNP formulation, QC labs, MSAT, and aseptic filling. Its proprietary platforms include in-house IVT and LNP formulation technology, scalable bioreactor capacity from 30L to 750L (with batch outputs from 100 mg up to 500 g of protein, 100 g of pDNA, and 50 g of mRNA), and a PPQ-validated E. coli-based Cas9 manufacturing process.
The company generates revenue through two streams: project-based GMP contract manufacturing services (process development, cell banking, GMP manufacturing, QC, aseptic filling, personalized batches with 4-week turnaround) and unit-based off-the-shelf catalog product sales through a webshop covering CRISPR/Cas9 nuclease, Cas9 mRNA variants, AAV and lentiviral starting plasmids, and recombinant allergens. Pricing is quote-based and not publicly disclosed for GMP services, while catalog items range from approximately €120 to €6,000 depending on grade (RUO vs GMP) and aliquot size. Its commercial footprint is predominantly Europe and the United States, served via direct enterprise sales, RFP-based engagement, and conference presence at CPhI, BIO Europe, ESGCT, ASGCT, and mRNA Health Conference events. Named anchor customers include BioNTech SE (DNA template supply for the Pfizer-BioNTech COVID-19 mRNA vaccine), Vertex Pharmaceuticals and CRISPR Therapeutics (cGMP manufacture of recombinant Cas9 for CASGEVY, the first FDA/EMA/MHRA-approved CRISPR/Cas9 therapy).
Biomay employs approximately 90 staff across its two Vienna sites, led by CEO Hans Huber (former Boehringer Ingelheim RCV bioprocess leader) and a senior team with deep CDMO and large-pharma pedigree. The company is privately owned with no disclosed VC or PE backing and operates without parent-company affiliation. Strategic priorities visible over 2024-2026 include FDA-approved commercial supply of Cas9 into the US market, an integrated end-to-end mRNA platform (now including LNP formulation), a growing off-the-shelf catalog franchise, the Areterna raw-materials partnership, and membership in the Alliance for mRNA Medicines.
Biomay AG firmographics
Firmographics- Name
- Biomay AG
- Legal name
- Biomay AG
- Website
- https://biomay.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Short description
- Biomay AG is a privately held Vienna-based CDMO offering GMP contract manufacturing of plasmid DNA, mRNA, and recombinant proteins, plus off-the-shelf catalog products, to biotech and pharma clients in Europe and the United States.
- Ownership category
- akta.pro rank
Biomay AG industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
Keywords
Where Biomay AG is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices2 records
Markets served
Biomay AG business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- CDMO Contract Manufacturing Services: Full-service Contract Development and Manufacturing Organization offering GMP manufacturing of plasmid DNA, mRNA, and recombinant proteins. Revenue generated through project-based contracts with biotech and pharma companies for clinical-stage and commercial manufacturing. Services include process development, cell banking, GMP manufacturing, quality control, and aseptic filling
- Off-the-Shelf Catalog Products: Sale of standardized products including CRISPR/Cas9 nuclease, Cas9 mRNA, AAV starting plasmids, lentiviral plasmids, and recombinant allergens through the company webshop. Products available in both RUO (research use only) and GMP grades. Revenue from unit-based product sales
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | CRISPR/Cas9 Nuclease RUO |
| Unit Pricing | Pay-as-you-go | CRISPR/Cas9 Nuclease GMP |
| Unit Pricing | Pay-as-you-go | Cas9 mRNA RUO |
| Unit Pricing | Pay-as-you-go | AAV Starting Plasmids |
| Unit Pricing | Pay-as-you-go | Lentivirus Plasmids |
| Unit Pricing | Pay-as-you-go | Recombinant Allergens |
| Other | Multi-year contract | GMP Manufacturing Services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Biomay AG product offering
Product offeringCore offering
Biomay AG is a GMP-licensed contract development and manufacturing organization (CDMO) headquartered in Vienna that produces plasmid DNA (pDNA), mRNA, and recombinant proteins using proprietary microbial expression platforms. The company provides end-to-end services spanning cell banking, upstream and downstream process development, GMP manufacturing, LNP formulation, and aseptic fill-finish for biotech and pharmaceutical clients. It also distributes a small catalog of research-use reagents and recombinant allergens.
Product overview
Biomay AG is a privately held, Vienna-based Contract Development and Manufacturing Organization (CDMO) offering GMP manufacturing services since 2009. The company operates as a one-stop manufacturer producing three core biomolecules: plasmid DNA (pDNA), messenger RNA (mRNA), and recombinant proteins. These are supported by comprehensive service offerings including GMP manufacturing, aseptic filling, personalized (patient-specific) batch production, and lipid nanoparticle (LNP) formulation services. Biomay's product portfolio also includes catalog products such as AAV and lentiviral starting plasmids, CRISPR/Cas9 nuclease, Cas9 mRNA, and recombinant allergens for research use. The company operates two GMP manufacturing sites in Vienna (headquarters in Seestadt Aspern and mRNA Competence Center in downtown Vienna) and is FDA-inspected.
Differentiator
Problem solved
Functional benefit
Products and services
- Plasmid DNA (pDNA) GMP Manufacturing Contract GMP manufacturing of plasmid DNA for gene therapy, cell therapy, and DNA vaccine developers using proprietary microbial fermentation processes.
- mRNA GMP Manufacturing Contract GMP manufacturing of mRNA active substance via in-vitro transcription, including personalized and batch mRNA production for therapeutic developers.
- Recombinant Protein Manufacturing Contract GMP manufacturing of recombinant proteins expressed in microbial hosts (E. coli, yeast) including HQ-grade and GMP-grade batches.
- Aseptic Filling Services Aseptic fill-finish of liquid vials for biologics, mRNA, and plasmid DNA products in a GMP environment.
- LNP Formulation Services Lipid nanoparticle (LNP) formulation of mRNA and nucleic acid drug substances for vaccine and therapeutic clients.
- Personalized Batch Manufacturing Small-scale, patient-specific GMP manufacturing of individualized mRNA or cell therapy drug substances for clinical use.
- HQ-Grade Recombinant Protein Production High-quality (HQ) recombinant protein production service for pre-clinical and research-grade material using microbial expression.
- CRISPR/Cas9 Nuclease (catalog) Catalogue research-use recombinant Cas9 nuclease protein supplied to gene editing researchers.
- Cas9 mRNA (catalog) Catalogue in-vitro transcribed Cas9 mRNA for gene editing research applications.
- AAV Starting Plasmids (catalog) Catalogue adeno-associated virus (AAV) packaging and starting plasmids sold to gene therapy developers.
- Lentiviral Plasmids (catalog) Catalogue lentiviral vector plasmids sold to cell and gene therapy researchers.
- Recombinant Allergens (catalog) Catalogue recombinant allergen proteins produced in microbial hosts for allergy research, diagnostics, and therapeutic developers.
Quantifiable outcome
- 200+ GMP-manufactured plasmid batches delivered
- +4 more outcomes
Companies that use Biomay AG
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles2 records
Biomay AG technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Biomay AG partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Alliance for mRNA Medicines (AMM)minorBiomay joined the Alliance for mRNA Medicines (AMM), the leading global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics and vaccines. Membership enables collaboration with industry leaders, contribution to setting industry standards, and support for development of safe and effective mRNA-based therapies worldwide. Biomay participates in AMM ASCENT annual meeting.
- Areterna LLCcoreStrategic partnership between Areterna LLC and Biomay AG to jointly serve mRNA CDMO customers in Europe and North America. Areterna supplies low-cost GMP raw materials including cap analogs and animal-origin-free nucleoside triphosphates (NTPs). Biomay provides GMP manufacturing of mRNA, pDNA, and recombinant proteins. Partnership enables European and American customers access to Areterna's raw materials while leveraging Biomay's 40 years of experience and 15+ years of GMP manufacturing. Biomay utilizes Areterna's cap analogs in GMP mRNA batches with satisfactory performance, yield, and quality.
- BioNTech SEcorePartnership with BioNTech to support supply chain for manufacturing of Pfizer-BioNTech COVID-19 mRNA vaccine. Biomay supplies DNA template for in-vitro transcription of mRNA active ingredient. Agreement initiated during clinical development phase in Q1/2020. Biomay became formally qualified supplier for BioNTech, providing process development, GMP preparation of cell bank, manufacturing of circular DNA plasmid, and preparation of linear DNA template. Multiple batches of released DNA template produced and delivered in 2021.
Scale indicators10 records
Recent moves8 records
Expansion highlights5 records
Biomay AG competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: World's largest CDMO offering microbial and mammalian-cell contract manufacturing for biologics, mRNA, and small molecules. Overlaps directly with Biomay on microbial pDNA, mRNA, and recombinant protein CDMO services, though at vastly larger scale and with a much broader modality portfolio.
- AGC Biologics: Global CDMO offering microbial and mammalian GMP manufacturing for recombinant proteins, viral vectors, and nucleic acid-based therapeutics. Directly comparable to Biomay on microbial-based protein CDMO services for clinical and commercial supply.
- Eurofins CDMO: Global CDMO network providing biologics manufacturing services including microbial and cell culture capabilities. Comparable to Biomay on contract GMP manufacturing for biological products, with broader service breadth.
- Thermo Fisher Scientific (Patheon / Brammer Bio): Diversified life sciences and CDMO business (including viral vector CDMO Brammer Bio) serving pharma and biotech with GMP manufacturing. Overlaps with Biomay on nucleic acid and gene therapy manufacturing services, with materially larger scale.
Direct peers
- Aldevron (Danaher): Specialist nucleic acid CDMO historically focused on plasmid DNA, mRNA, and proteins for gene therapy and cell therapy developers. Highly comparable to Biomay in offering GMP pDNA and mRNA manufacturing with off-the-shelf catalog products (e.g., catalog Cas9); now part of Danaher, expanding scale.
- Kaneka Eurogentec: Belgian-Japanese CDMO specializing in GMP plasmid DNA and oligonucleotide manufacturing for gene therapy and nucleic-acid applications. Closely comparable to Biomay's pDNA manufacturing platform with similar customer profile.
- TriLink BioTechnologies ( Maravai LifeSciences): Specialist CDMO for mRNA, plasmid DNA, and nucleic acid reagents with both custom GMP services and a strong catalog product offering. Directly comparable to Biomay on mRNA and pDNA CDMO services, and an employer of Biomay's VP BD May Guo prior to Biomay.
- Celonic Group: Specialist GMP CDMO for biologics including recombinant proteins, viral vectors, and cell therapies, with a European (German/Swiss) footprint. Comparable to Biomay as a European-headquartered microbial-experienced CDMO serving clinical-stage developers.
- ReciBioPharm (Recipharm): CDMO offering development and GMP manufacturing for biologics including microbial-derived proteins and nucleic-acid-based therapies. Directly comparable as a microbial-CDMO competitor; also a prior employer of Biomay's VP BD May Guo.
Others
- BIA Separations (Sartorius): Specialist in chromatographic purification for large DNA plasmids and viral vectors, now part of Sartorius. An existing technology partner of Biomay (May 2018 collaboration on double-digit gram-scale plasmid purification) and an adjacent enabling-technology peer in the plasmid/viral vector CDMO ecosystem.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biomay AG social profiles
Digital presenceBiomay AG compliance and trust
Trust signalCompliance4 records
Biomay AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biomay AG leadership team
Management profileNumber of profiles
Profiles9 records
Biomay AG subsidiaries and ownership
Company hierarchySubsidiaries2 records
Biomay AG funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biomay AG M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biomay AG
What does Biomay AG do?
Biomay AG is a GMP-licensed contract development and manufacturing organization (CDMO) headquartered in Vienna that produces plasmid DNA (pDNA), mRNA, and recombinant proteins using proprietary microbial expression platforms. The company provides end-to-end services spanning cell banking, upstream and downstream process development, GMP manufacturing, LNP formulation, and aseptic fill-finish for biotech and pharmaceutical clients. It also distributes a small catalog of research-use reagents and recombinant allergens.
Is Biomay AG a public or private company?
Biomay AG is a private company. It is classified as unknown and is currently operating.
When was Biomay AG founded?
Biomay AG was founded in 1984.
Where is Biomay AG based?
Biomay AG is headquartered in Vienna, Austria, in the Europe region.
How does Biomay AG make money?
Two revenue lines are on record. CDMO Contract Manufacturing Services are the primary driver. The others are off-the-Shelf Catalog Products.
Who are Biomay AG's main competitors?
Broad incumbents on record are Lonza Group, AGC Biologics, Eurofins CDMO and Thermo Fisher Scientific (Patheon / Brammer Bio). Direct peers are Aldevron (Danaher), Kaneka Eurogentec, TriLink BioTechnologies ( Maravai LifeSciences), Celonic Group and ReciBioPharm (Recipharm). BIA Separations (Sartorius) is listed as an others.
Does Biomay AG have an API?
No public API is recorded for Biomay AG.
What industry is Biomay AG in?
Biomay AG's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 8731.